Probing the safety of medications in the frail elderly: Evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents

Journal of Clinical Psychiatry

Volumn 64, Issue 8, 2003, Pages 875-882

  Oslin, David W ^a,b,c   Ten Have, Thomas R ^a   Streim, Joel E ^a   Datto, Catherine J ^a,b   Weintraub, Daniel ^a,b   DiFilippo, Suzanne ^a   Katz, Ira R ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SERTRALINE; VENLAFAXINE;

ADULT; AGE; AGED; AGITATION; ANEMIA; ANXIETY; ARTICLE; BRADYCARDIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DEMENTIA; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; FALLING; FATIGUE; FEMALE; FRACTURE; HAMILTON SCALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; HYPONATREMIA; INFORMED CONSENT; INTERSTITIAL LUNG DISEASE; IRRITABILITY; KIDNEY DYSFUNCTION; KNEE FRACTURE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NURSING HOME; OUTCOMES RESEARCH; PNEUMONIA; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; T WAVE INVERSION; THORAX PAIN; THROMBOCYTOPENIA; UNITED STATES; URINARY TRACT INFECTION; UROSEPSIS;

EID: 0041511646     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0804     Document Type: Article

References (49)

1. Field TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001;161:1629-1634
2. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000;109:87-94
3. Ghose K. The need for a review journal of drug use and the elderly. Drugs Aging 1991;1:2-5
4. Nolan L, O'Malley K. Adverse drug reactions in the elderly. Br J Hosp Med 1989;41:446,448,452-457
5. Nolan L, O'Malley K. The need for a more rational approach to drug prescribing for elderly people in nursing homes. Age Ageing 1989;18:52-56
6. Heston LL, Garrard J, Makris L, et al. Inadequate treatment of depressed nursing home elderly. J Am Geriatr Soc 1992;40:1117-1122
7. American Society of Consultant Pharmacists. HCFA OSCAR Data fact sheet, 2002
8. Datto CJ, Oslin DW, Streim JE, et al. Pharmacologic treatment of depression in nursing home residents: a mental health services perspective. J Geriatr Psychiatry Neurol 2002;15:141-146
9. Thapa PB, Gideon P, Cost TW, et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998;339:875-882
10. Magai C, Kennedy G, Cohen CI, et al. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry 2000;8:66-74
11. Oslin DW, Streim JE, Katz IR, et al. Heuristic comparison of sertraline with nortriptyline for the treatment of depression in frail elderly patients. Am J Geriatr Psychiatry 2000;8:141-149
12. Rosen J, Mulsant BH, Pollock BG. Sertraline in the treatment of minor depression in nursing home residents: a pilot study. Int J Geriatr Psychiatry 2000;15:177-180
13. Trapper B, Cohen CI. Use of SSRIs in "very old" depressed nursing home residents. Am J Geriatr Psychiatry 1998;6:83-89
14. Trapper B, Cohen CI. Using fluoxetine in "very old" depressed nursing home residents. Am J Geriatr Psychiatry 1996;4:258-262
15. Alexopoulos GS, Katz IR, Reynolds CF III, et al, The Expert Consensus Guideline Series: Pharmacotherapy of Depressive Disorders in Older Patients. Postgrad Med Spec Rep Oct 2001
16. Nierenberg AA. Do some antidepressants work faster than others? J Clin Psychiatry 2001;62(suppl 15):22-25
17. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241
18. Stahl SM, Nierenberg AA, Gorman JM. Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry 2001;62(suppl 4):17-23; discussion 37-40
19. Entsuah R, Derivan A, Kikta D. Early onset of antidepressant action of venlafaxine: pattern analysis in intent-to-treat patients. Clin Ther 1998;20:517-526
20. Staab JP, Evans DL. Efficacy of venlafaxine in geriatric depression. Depress Anxiety 2000;12(suppl 1):63-68
21. Streim JE, Oslin DW, Katz IR, et al. Drug treatment of depression in frail elderly nursing home residents. Am J Geriatr Psychiatry 2000;8:150-159
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
23. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression scale. J Psychiatr Res 1983;17:31-49
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-65
25. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral gray matter of elderly subjects. Br J Psychiatry 1968;114:797-811
26. Katzman R, Brown T, Thal LJ, et al. Comparison of rate of annual change of mental status score in four independent studies of patients with Alzheimer's disease. Ann Neurol 1988;24:384-389
27. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
28. Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992;41:237-248
29. Parmelee PA, Thuras PD, Katz IR, et al. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995;9:179-188
30. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186
31. Alexopoulos GS, Abrams RC, Young RC, et al. Cornell Scale for Depression in Dementia. Biol Psychiatry 1988;23:271-284
32. Guy W. Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
33. Asberg M, Cronholm B, Sjoqvist F, et al. Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J 1970;4:18-21
34. Ten Have TR, Kunselman AR, Pulkstenis EP, et al. Mixed effects logistic regression models for longitudinal binary response data with informative drop-out. Biometrics 1998;54:367-383
35. Katz IR, Reynolds CF III, Alexopoulos GS, et al. Venlafaxine ER as a treatment for generalized anxiety in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc 2002;50:18-25
36. Smeraldi E, Rizzo F, Crespi G. Double-blind, randomized study of venlafaxine, clomipramine and trazodone in geriatric patients with major depression. Primary Care Psychiatry 1998;4:189-195
37. Schatzberg A, Cantillon M. Antidepressant early response and remission with venlafaxine or fluoxetine in depressed geriatric outpatients. Presented at the 22nd Collegium Internationale Neuro-Psychopharmacologicum; July 9-13, 2000; Brussels, Belgium. New Research P.03.048
38. Mahapatra SN, Hackett D. A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Int J Clin Pract 1997;51:209-213
39. Amore M, Ricci M, Zanardi R, et al. Long-term treatment of geropsychiatric depressed patients with venlafaxine. J Affect Disord 1997;46:293-296
40. Dierick M. An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry 1996;8:169-178
41. Zimmer B, Kant R, Zeiler D, et al. Antidepressant efficacy and cardiovascular safety of venlafaxine in young vs old patients with comorbid medical disorders. Int J Psychiatry Med 1997;27:353-364
42. Kahn A, Rudulph R, Baumel B, et al. Venlafaxine in depressed geriatric outpatients: an open-label clinical study. Psychopharmacol Bull 1995;31:753-758
43. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000;57:503-509
44. Abdelmawla AH, Langley RW, Szabadi E, et al. Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. Br J Clin Pharmacol 1999;48:345-354
45. Shores MM, Pascluay M, Lewis NL, et al. Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinology 2001;26:433-439
46. Schroeder C, Tank J, Boschmann M, et al. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation 2002;105:347-353
47. Andreoli V, Carbognin G, Abati A, et al. Reboxetine in the treatment of depression in the elderly: pilot study. J Geriatr Psychiatry Neurol 1999;12:206-210
48. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf 2001;24:183-197
49. Katz IR, Simpson GM, Curlik SM, et al. Pharmacologic treatment of major depression for elderly patients in residential care settings. J Clin Psychiatry 1990;51(suppl 7):41-47